Vaxart, Inc. to Participate in September Virtual Investor Conferences
- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th – 16th
- Sachs Associates: 20th Annual Biotech in Europe Forum - September 21st – 24th
- SVB Leerink: CybeRx Series: Vaccine Forum - September 23rd & – 24th
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc.. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced senior management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:
| H.C. Wainwright: 22nd Annual Global Investment Conference | |
| Title: | Vaxart, Inc. (VXRT) Company Presentation / Fireside Chat |
| Date: | Monday, September 14th 2020 |
| Time: | 10:30 am Eastern Time |
| Presenter: | Andrei Floroiu, President & CEO |
| Sachs Associates: 20th Annual Biotech in Europe Forum | |
| Title (1): | Pandemic Response Day:Vaccine Panel |
| Date: | Monday, September 21st 2020 |
| Time: | 13:05 -14:00 Central European Time |
| Panelists: | Andrei Floroiu, President & CEOVaxart, Inc. |
| Andrew Allen, Co-Founder, President & CEO, Gritstone Oncology | |
| Frederic Ors, CEO, IMV, Inc. | |
| Johan Van Hoof, Global Therapeutic Area Head, IDV Vaccines, Johnson & Johnson | |
| Title (2): | Spotlight Showcase Vaxart, Inc. (VXRT) Company Presentation |
| Date: | Monday, September 21st 2020 |
| Time: | 14:05 -14:25 Central European Time |
| Presenter: | Andrei Floroiu, President & CEOVaxart, Inc. |
| SVB LEERINK: CybeRx Series – Vaccine Forum | |
| Title: | Vaxart, Inc. (VXRT) - Fireside Chat |
| Date: | Wednesday, September 23rd 2020 |
| Time: | 2:00 am Eastern Time |
| Presenters: | Andrei Floroiu, President & CEO |
| Sean Tucker, Ph.D., Founder & Chief Scientific Officer | |
Webcast Links
A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Company’s website.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet vaccine is easier to distribute, store and administer than injectable vaccines and may provide significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit www.vaxart.com.
Contacts
Investors:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
617.435.6602
Media:
Gloria Gasaatura
LifeSci Communications
GGasaatura@lifescicomms.com
646.970.4688
